Parisa Zamiri, MD, PhD, is a physician-scientist with deep expertise in drug discovery and development. She is an ophthalmologist by training with clinical experience in medical retina, immunology, and inflammation.
Dr. Zamiri most recently served as the Chief Medical Officer at Complement Therapeutics and previously at Graybug Vision, where she oversaw clinical, regulatory, medical affairs and biostatistics. Prior to that, she served as Vice President, Global Head of Clinical Development and Therapeutic Area Head for Ophthalmology at Novartis Pharmaceuticals leading a group of clinical scientists and ophthalmologists that designed and executed Phase 1 to Phase 4 clinical trials with novel biologics, gene therapies, small molecules, and digital therapeutics for ophthalmic indications, such as wet AMD, geographic atrophy, retinitis pigmentosa and dry eye.
Dr. Zamiri received her medical degree from the King’s College Hospital, University of London, and did her ophthalmology residency at the North Thames Rotation, affiliated with the Moorfields Eye Hospital in London. She earned her PhD in ocular immunology for her research on the immune privilege of the subretinal space, conducted at the Schepens Eye Research Institute of Massachusetts Eye and Ear, a Harvard Medical School affiliated institute.